ENGR. S. A. TO ENGR. H. B. NO. 3073 Page 1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
ENGROSSED SENATE AMENDMENTS
TO
ENGROSSED HOUSE
BILL NO. 3073 By: Talley, Randleman, Bush,
Miller, Echols, Pittman and
Stinson of the House
and
Rader of the Senate
An Act relating to public health and safety; amending
63 O.S. 2021, Section 2-101, which relates to
definitions of the Uniform Controlled D angerous
Substances Act; defining palliative care; amending 63
O.S. 2021, Section 2 -309I, which relates to the Anti -
Drug Diversion Act; add ing an exception; providing
statutory reference; and declaring an emergency.
AUTHOR: Add the following House Coauthor: Goodwin
AUTHOR: Add the following Senate Coauthors: Dugger, Matthews, and
Young
AMENDMENT NO. 1. Page 1, line 24, through page 24, line 2, by
deleting Section 1 and renumbering subsequent
sections
AMENDMENT NO. 2. Page 29, lines 4 and 5, by deleting after the word
“care” on Line 4 and before the word “in” on Line
5, all new language
and amend the title to conform
ENGR. S. A. TO ENGR. H. B. NO. 3073 Page 2 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Passed the Senate the 25th day of April, 2022.
Presiding Officer of the Senate
Passed the House of Representatives the ____ day of __________,
2022.
Presiding Officer of the House
of Representatives
ENGR. H. B. NO. 3073 Page 1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
ENGROSSED HOUSE
BILL NO. 3073 By: Talley, Randleman, Bush,
Miller, Echols, Pittman and
Stinson of the House
and
Rader of the Senate
An Act relating to public health and safety; amending
63 O.S. 2021, Section 2-101, which relates to
definitions of the Uniform Controlled D angerous
Substances Act; defining palliative care; amending 63
O.S. 2021, Section 2 -309I, which relates to the Anti -
Drug Diversion Act; add ing an exception; providing
statutory reference; and declaring an emergency .
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. AMENDATORY 63 O.S. 2021, Sectio n 2-101, is
amended to read as follows:
Section 2-101. As used in the Uniform Controlled Dangerous
Substances Act:
1. "Administer" means the direct application of a controlled
dangerous substance, whether by injec tion, inhalation, ingestion or
any other means, to the body of a patient, animal or research
subject by:
ENGR. H. B. NO. 3073 Page 2 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. a practitioner (or, in the presence of the
practitioner, by the authorize d agent of the
practitioner), or
b. the patient or research subject at the direction and
in the presence of the prac titioner;
2. "Agent" means a peace officer appointe d by and who acts on
behalf of the Director of the Oklahoma State Bureau of Narcotics an d
Dangerous Drugs Cont rol or an authorized person who acts on behalf
of or at the direction of a person who manufact ures, distributes,
dispenses, prescribes, administer s or uses for scientific purposes
controlled dangerous substances but does not include a common or
contract carrier, public warehouser or employee thereof, or a pe rson
required to register under the Unifo rm Controlled Dangerous
Substances Act;
3. "Board" means the Advisory Board to the Direc tor of the
Oklahoma State Bureau of Narcotics and D angerous Drugs Control ;
4. "Bureau" means the Oklahoma State Bureau of Nar cotics and
Dangerous Drugs Control;
5. "Coca leaves" includes cocaine and any compound,
manufacture, salt, derivative, mixture or preparation of coca
leaves, except derivatives of coca leaves which do n ot contain
cocaine or ecgonine;
6. "Commissioner" or "Director" means the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
ENGR. H. B. NO. 3073 Page 3 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
7. "Control" means to add, remove or change the placement of a
drug, substance or immediate precurso r under the Uniform Controlled
Dangerous Substances A ct;
8. "Controlled dangerous substance " means a drug, substance or
immediate precursor in Sc hedules I through V of the Uniform
Controlled Dangerous Substances Act or any drug, subs tance or
immediate precursor listed either temporarily or permanently as a
federally controlled substance . Any conflict between state and
federal law with regard to th e particular schedule in which a
substance is listed shall be resolved in favor of state law;
9. "Counterfeit substance" means a controlled substance which,
or the container or labeling of which without authorization, bears
the trademark, trade name or ot her identifying marks, imprint,
number or device or any likeness thereof of a manufactur er,
distributor or dispenser other than the person who in fact
manufactured, distributed or dispensed the substance;
10. "Deliver" or "delivery" means the actual, cons tructive or
attempted transfer from o ne person to another of a controlled
dangerous substance or drug parapher nalia, whether or not there is
an agency relationship ;
11. "Dispense" means to deliver a cont rolled dangerous
substance to an ultimate user or h uman research subject by or
pursuant to the lawful order of a practitioner, including the
prescribing, administ ering, packaging, labeling or compounding
ENGR. H. B. NO. 3073 Page 4 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
necessary to prepare the substance for such distribu tion.
"Dispenser" is a practitioner who delivers a controlled dangerous
substance to an ultimate user or human research subject;
12. "Distribute" means to deliver other than by administering
or dispensing a contro lled dangerous substance;
13. "Distributor" means a commercial entity engaged in the
distribution or reverse distribution of narc otics and dangerous
drugs and who complies with all regulations promulgat ed by the
federal Drug Enforcement Administration and the Oklahoma State
Bureau of Narcotics a nd Dangerous Drugs Control;
14. "Drug" means articles:
a. recognized in the official Uni ted States Pharmacopeia,
official Homeopathic Pharm acopoeia of the United
States, or official National Formulary, or any
supplement to any of them,
b. intended for use in the diagnosis, cure, mitigation,
treatment or prevention of disease in man or other
animals,
c. other than food, intended to affect the structure or
any function of the body of man or other animals, and
d. intended for use as a component of any article
specified in this paragraph;
provided, however, the term "drug" does not include devices or their
components, parts or accessories;
ENGR. H. B. NO. 3073 Page 5 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
15. "Drug-dependent person" means a person who is using a
controlled dangerous su bstance and who is in a state of psychic or
physical dependence, or both, arising from administration of that
controlled dangerous substance on a continuous basis . Drug
dependence is characterized by be havioral and other responses which
include a strong compulsion to take the substance on a cont inuous
basis in order to experience its psychic effects, or to avoid the
discomfort of its absence;
16. "Home care agency" means any sole proprietorship,
partnership, association, corporation, or other organization which
administers, offers, or provides h ome care services, for a fee or
pursuant to a contract for such services, to clients in t heir place
of residence;
17. "Home care services" means skilled or perso nal care
services provided to clients in their place of residence for a fee;
18. "Hospice" means a centrally administered, nonprofit or for-
profit, medically directed, nurse -coordinated program which provides
a continuum of home and inpatient care for the terminally ill
patient and the patient 's family. Such term shall also include a
centrally administered, nonprofit or for-profit, medically directed,
nurse-coordinated program if suc h program is licensed pursuant to
the provisions of the Uniform Controlle d Dangerous Substances Act .
A hospice program offers palliative and supportive care to meet t he
special needs arising out of the physical, emotional and spiritual
ENGR. H. B. NO. 3073 Page 6 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
stresses which are experienced during the final stages of illness
and during dying and berea vement. This care is available twenty -
four (24) hours a day, seven (7) days a week, and is pr ovided on the
basis of need, regardless of ability to pay. "Class A" Hospice
refers to Medicare-certified hospices. "Class B" refers to all
other providers of h ospice services;
19. "Imitation controlled substance " means a substance that is
not a controlled dangerous substance, which by dosage unit
appearance, color, shape, size, markings or by representations made,
would lead a reasonable p erson to believe that the substance is a
controlled dangerous substance . In the event the appearance of the
dosage unit is not reasonably sufficient to establish that the
substance is an "imitation controlled substance", the court or
authority concerned s hould consider, in add ition to all other
factors, the following factors as related to "representations made "
in determining whether the substance is an "imitation controlled
substance":
a. statements made by an owner or by any other person in
control of the substance concerning the nature of the
substance, or its use or effect,
b. statements made to the recipient that t he substance
may be resold for inordinate profit,
c. whether the substance is packaged in a manner normally
used for illicit controlled subs tances,
ENGR. H. B. NO. 3073 Page 7 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. evasive tactics or actions utilized by the owner or
person in control of the substance to avoid detection
by law enforcement authorities,
e. prior convictions, if any, of an owner, or any other
person in control of the object, under state or
federal law related to co ntrolled substances or fraud,
and
f. the proximity of the substances to controlled
dangerous substances;
20. "Immediate precursor" means a substance which the Director
has found to be and by regulation designates as being the princip al
compound commonly used or produced primarily for use, and which is
an immediate chemical intermediary used, or li kely to be used, in
the manufacture of a controlled dangerous substance, the control of
which is necessary to prevent, curtail or limit such manufacture;
21. "Laboratory" means a laboratory approved by the Director as
proper to be entrusted with the custo dy of controlled dangerous
substances and the use of controlled dangerous substances for
scientific and medical purposes and for purposes of instruction;
22. "Manufacture" means the production, preparation,
propagation, compounding or processing of a cont rolled dangerous
substance, either directly or indir ectly by extraction from
substances of natural or synthetic origin, or independently by means
of chemical synthesis or by a combination of extraction and chemical
ENGR. H. B. NO. 3073 Page 8 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
synthesis. "Manufacturer" includes any person who packages,
repackages or labels any contain er of any controlled dangerous
substance, except practitioners who dispense or compound
prescription orders fo r delivery to the ultimate consumer;
23. "Marijuana" means all parts of the plant Cannabis sa tiva
L., whether growing or not; the seeds thereof; the resin extracted
from any part of such plant; and every compound, manufacture, salt,
derivative, mixture or preparation of such plant, its seeds or
resin, but shall not include:
a. the mature stalks of such plant or fiber produced from
such stalks,
b. oil or cake made from the seeds of suc h plant,
including cannabidiol derived from the see ds of the
marijuana plant,
c. any other compound, manufacture, salt, deriva tive,
mixture or preparation of such matu re stalks (except
the resin extracted therefrom), in cluding cannabidiol
derived from mature stalks, fiber, oil or cake,
d. the sterilized seed of such plant which is incapable
of germination,
e. for any person parti cipating in a clinical trial to
administer cannabidiol for the treatment of severe
forms of epilepsy pursuant to Section 2 -802 of this
title, a drug or substance approved by the fed eral
ENGR. H. B. NO. 3073 Page 9 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Food and Drug Administration for use by those
participants,
f. for any person or the parents, legal guardians o r
caretakers of the person who have received a writt en
certification from a physician lic ensed in this state
that the person has been diagno sed by a physician as
having Lennox-Gastaut syndrome, Dravet syndrome, also
known as severe myoclonic epilepsy of i nfancy, or any
other severe form of epilepsy that is not adequately
treated by traditional medical therapies, spasticity
due to multiple scle rosis or due to parapl egia,
intractable nausea and vomiting, appetite stimu lation
with chronic wasting diseases, the substance
cannabidiol, a nonpsychoactive cannabinoi d, found in
the plant Cannabis sativa L. or any other preparation
thereof, that has a te trahydrocannabinol con centration
of not more than three -tenths of one percent (0.3%)
and that is delivered to the pa tient in the form of a
liquid,
g. any federal Food-and-Drug-Administration-approved drug
or substance, or
h. industrial hemp, from the plant Cannabis sativa L. an d
any part of such plant, whether growing or not, wit h a
delta-9 tetrahydrocannabinol concentr ation of not more
ENGR. H. B. NO. 3073 Page 10 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
than three-tenths of one percent ( 0.3%) on a dry
weight basis which sha ll only be grown pursuant to the
Oklahoma Industrial Hemp Program and may be shipped
intrastate and interstate;
24. "Medical purpose" means an intention to utilize a
controlled dangerous substance for physical or menta l treatment, for
diagnosis, or for th e prevention of a disease condition not in
violation of any state or fede ral law and not for the purpose of
satisfying physiological or psychological dependence or oth er abuse;
25. "Mid-level practitioner" means an Advanced Practice
Registered Nurse as de fined and within parameters specified in
Section 567.3a of Title 59 of th e Oklahoma Statutes, or a certified
animal euthanasia technician as defined in Section 698.2 o f Title 59
of the Oklahoma Statutes, or an animal co ntrol officer registered by
the Oklahoma State Bureau of Narcotics and Dangerous Drugs C ontrol
under subsection B of Section 2-301 of this title within the
parameters of such officer's duties under Sections 501 through 508
of Title 4 of the Oklahoma Statut es;
26. "Narcotic drug" means any of the following, whether
produced directly or indire ctly by extraction fro m substances of
vegetable origin, or independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:
a. opium, coca leaves and opiates,
ENGR. H. B. NO. 3073 Page 11 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
b. a compound, manufacture, salt, derivative or
preparation of opium, coca leave s or opiates,
c. cocaine, its salts, optical and geom etric isomers, and
salts of isomers,
d. ecgonine, its derivatives, their salts, isomers and
salts of isomers, and
e. a substance, and any compound, manufacture, salt,
derivative or preparation thereof, w hich is chemically
identical with any of the substanc es referred to in
subparagraphs a through d of this paragraph, except
that the words "narcotic drug" as used in Section 2 -
101 et seq. of this title shall not include
decocainized coca leaves or extracts of coca leaves,
which extracts do not contain cocaine or ecgonine;
27. "Opiate" or "opioid" means any Schedule II, III, IV or V
substance having an addiction-forming or addiction -sustaining
liability similar to morphine or being capa ble of conversion into a
drug having such addiction -forming or addiction -sustaining
liability. The terms do not inc lude, unless specifically designated
as controlled under the Uniform Controlled Dangerous Substances Act,
the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its
salts (dextromethorphan) . The terms do include the racemic and
levorotatory forms;
ENGR. H. B. NO. 3073 Page 12 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
28. "Opium poppy" means the plant of the species Pa paver
somniferum L., except the seeds thereof;
29. "Palliative care" means patient-centered and family-focused
medical care that optimizes quality of life by anti cipating,
preventing, and treating suffer ing caused by a medical illness or a
physical injury or condition that substantially affe cts the quality
of life of a patient . Palliative care includes, but is not limited
to:
a. addressing physical, emotional, social, and spiritual
needs,
b. facilitating patient autonomy and choice of care,
c. providing access to information,
d. discussing the goals of treatment for the patient and
treatment options including, wh en appropriate, hospice
care, and
e. managing pain and symptoms comprehensively.
Palliative care does not always include a requirement for hospice
care or attention to sp iritual needs;
30. "Peace officer" means a police officer, sher iff, deputy
sheriff, district attorney's investigator, investigator from th e
Office of the Attorney General, or any other person elected or
appointed by law to enforce any of the criminal laws of this state
or of the United States;
ENGR. H. B. NO. 3073 Page 13 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
30. 31. "Person" means an individual, corpora tion, government
or governmental subdivision or agenc y, business trust, estate,
trust, partnership or association, or any other legal entity;
31. 32. "Poppy straw" means all parts, except the seeds , of the
opium poppy, after mowing;
32. 33. "Practitioner" means:
a. (1) a medical doctor or osteopathic physi cian,
(2) a dentist,
(3) a podiatrist,
(4) an optometrist,
(5) a veterinarian,
(6) a physician assistant or Advanced Practice
Registered Nurse under the supervision of a
licensed medical doctor or osteop athic physician,
(7) a scientific investigator, or
(8) any other person,
licensed, registered or otherwise permitted to
prescribe, distribute, dis pense, conduct research with
respect to, use for sci entific purposes or administer
a controlled dangerous subs tance in the course of
professional practice or resea rch in this state, or
b. a pharmacy, hospital, laboratory or other institution
licensed, registered or otherwise permitted to
distribute, dispense, conduct research with respect
ENGR. H. B. NO. 3073 Page 14 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
to, use for scientific pu rposes or administer a
controlled dangerous substance in the course of
professional practice o r research in this state;
33. 34. "Production" includes the manufacture, planting,
cultivation, growing or harvesting of a controlled dange rous
substance;
34. 35. "State" means the State of Oklahoma or any other s tate
of the United States;
35. 36. "Ultimate user" means a person who lawfully possesses a
controlled dangerous substance for the person 's own use or for the
use of a member of the person's household or for administration to
an animal owned by the person or by a member of the person's
household;
36. 37. "Drug paraphernalia" means all equipment, products and
materials of any kind which are used, i ntended for use, or fashioned
specifically for use in plan ting, propagating, cultivating, growing,
harvesting, manufacturing, compounding, converting, p roducing,
processing, preparing, testing, analyzing, packaging, repackaging,
storing, containing, concea ling, injecting, ingesting, inhaling or
otherwise introducing into the human body, a controlled dangerous
substance in violation of the Uniform Controll ed Dangerous
Substances Act inclu ding, but not limited to:
a. kits used, intended for use, or fashioned specifically
for use in planting, pr opagating, cultivating , growing
ENGR. H. B. NO. 3073 Page 15 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
or harvesting of any species of plant which is a
controlled dangerous substance or f rom which a
controlled dangerous substance can be derived,
b. kits used, intended for use, or fashioned specifically
for use in manufacturin g, compounding, conver ting,
producing, processing or preparing controlled
dangerous substances,
c. isomerization devices used, intended for use, or
fashioned specifically for use in increasing the
potency of any species of plant which is a controlled
dangerous substance,
d. testing equipment used, intended for use, or fashioned
specifically for use in identifying, or in analyzing
the strength, effectiv eness or purity of controlled
dangerous substances,
e. scales and balances used, intended for use, or
fashioned specifically for use in weighing or
measuring controlled dangerous sub stances,
f. diluents and adulterants, suc h as quinine
hydrochloride, manni tol, mannite, dextrose and
lactose, used, intended for use, or fashione d
specifically for use in cutting co ntrolled dangerous
substances,
ENGR. H. B. NO. 3073 Page 16 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
g. separation gins and sifters used, intende d for use, or
fashioned specifically for use in removing twigs and
seeds from, or in otherwise cleaning or refining,
marijuana,
h. blenders, bowls, containers, spoons and mixing dev ices
used, intended for use, or fashioned specifically for
use in compounding controlled dangerous substances,
i. capsules, balloons, envelopes and o ther containers
used, intended for use, or fashioned specifically for
use in packaging small quantities of controlled
dangerous substances,
j. containers and other objects used, inte nded for use,
or fashioned specifically f or use in parenterally
injecting controlled dangerous substances into the
human body,
k. hypodermic syringes, needles and other objects used ,
intended for use, or fashioned specifically for use in
parenterally injecting controlled dangerous substances
into the human body,
l. objects used, intended for use, or fashioned
specifically for use in ingesting, inha ling or
otherwise introducing mariju ana, cocaine, hashish or
hashish oil into the human body, such as:
ENGR. H. B. NO. 3073 Page 17 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(1) metal, wooden, acrylic, glass, stone, plasti c or
ceramic pipes with or without screens, permanent
screens, hashish heads or punctured metal bowls,
(2) water pipes,
(3) carburetion tubes and devices,
(4) smoking and carburetion masks,
(5) roach clips, meaning o bjects used to hold burning
material, such as a marijuana cigarette, that has
become too small or too short to be held in the
hand,
(6) miniature cocaine spoons and cocaine vials,
(7) chamber pipes,
(8) carburetor pipes,
(9) electric pipes,
(10) air-driven pipes,
(11) chillums,
(12) bongs, or
(13) ice pipes or chillers,
m. all hidden or novelty pipes, and
n. any pipe that has a tobacco bowl or cham ber of less
than one-half (1/2) inch in diameter in which there is
any detectable residue of any controlled dan gerous
substance as defined in this section or any other
substances not legal for possession or use;
ENGR. H. B. NO. 3073 Page 18 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
provided, however, the term "drug paraphernalia" shall not include
separation gins intended for use in preparing tea or spice, clamps
used for constructing electrical equipment, water pipes designed for
ornamentation in which no detectable amount of an illegal substance
is found or pipes designed an d used solely for smoking tobacco,
traditional pipes of an American Indian tribal religious ceremony,
or antique pipes that are thirty (30) years of age or older;
37.
38. a. "Synthetic controlled substance" means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure o f a controlled
dangerous substance in Schedule I or I I,
(2) which has a stimulant, depressant, or
hallucinogenic effect on the cent ral nervous
system that is substantially similar to or
greater than the stimulant, depressant or
hallucinogenic effect on the central nervous
system of a controlled dangerous sub stance in
Schedule I or II, or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
depressant, or hallucinogenic effect on the
central nervous system tha t is substantially
similar to or greater than the sti mulant,
ENGR. H. B. NO. 3073 Page 19 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
depressant, or hallucinogenic effect on the
central nervous system of a controlled dangerous
substance in Schedule I or II.
b. The designation of gamma butyrolactone or any other
chemical as a precursor, pursuant to Section 2 -322 of
this title, does not preclude a finding pursuant to
subparagraph a of this paragraph that the chemical is
a synthetic controlled substance.
c. "Synthetic controlled substance" does not include:
(1) a controlled dangero us substance,
(2) any substance for which there is an approved new
drug application,
(3) with respect to a particular person any
substance, if an exemption is in effect for
investigational use, for that person under the
provisions of Section 505 of the Fed eral Food,
Drug and Cosmetic Act, Title 21 of the Uni ted
States Code, Section 355, to the exte nt conduct
with respect to such subst ance is pursuant to
such exemption, or
(4) any substance to the ext ent not intended for
human consumption before such an exem ption takes
effect with respect to that substance.
ENGR. H. B. NO. 3073 Page 20 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. Prima facie evidence that a substance co ntaining
salvia divinorum has been en hanced, concentrated or
chemically or physically altered shall give rise to a
rebuttable presumption th at the substance is a
synthetic controlled substance;
38. 39. "Tetrahydrocannabinols" means all substances that have
been chemically synthesized to emulate the tetrahydrocannabinols of
marijuana;
39. 40. "Isomer" means the optical isomer, except as used in
subsections C and F of Section 2-204 of this title and paragraph 4
of subsection A of Section 2-206 of this title. As used in
subsections C and F of Section 2-204 of this title, "isomer" means
the optical, positional or geometric isomer. As used in paragraph 4
of subsection A of Section 2-206 of this title, the term "isomer"
means the optical or geometric isomer;
40. 41. "Hazardous materials" means materials, whether solid,
liquid or gas, which are toxic to human, a nimal, aquatic or plant
life, and the disposal of which ma terials is controlled by state or
federal guidelines;
41. 42. "Anhydrous ammonia" means any substance that exhibits
cryogenic evaporative behavio r and tests positive for ammonia;
42. 43. "Acute pain" means pain, whether resulting fr om
disease, accidental or intentional trauma or other cause, that the
practitioner reasonably expects to las t only a short period of time .
ENGR. H. B. NO. 3073 Page 21 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
"Acute pain" does not include chronic pain, pain being treated as
part of cancer care, hospice or other end-of-life care, or pain
being treated as part of palliative care;
43. 44. "Chronic pain" means pain that persists beyond the
usual course of an acute disease or healing of an in jury. "Chronic
pain" may or may not be associated w ith an acute or chronic
pathologic process that causes con tinuous or intermittent pain over
months or years;
44. 45. "Initial prescription" means a prescription issued to a
patient who:
a. has never previously been issued a prescription for
the drug or its pharmaceutical equivalent in the p ast
year, or
b. requires a prescription for the drug or its
pharmaceutical equivalent due to a surgical procedur e
or new acute event and has previously had a
prescription for the drug or its pharmaceutical
equivalent within the past year.
When determining whether a patient was previously issued a
prescription for a drug or its ph armaceutical equivalent, the
practitioner shall consult with the patient and review the medic al
record and prescription monitoring information of the patient;
45. 46. "Patient-provider agreement" means a written contract
or agreement that is executed betw een a practitioner and a patient,
ENGR. H. B. NO. 3073 Page 22 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
prior to the commencement of treatment for chronic pain usi ng an
opioid drug as a means to:
a. explain the possible risk of development of physical
or psychological depe ndence in the patient and prevent
the possible development of addiction,
b. document the understanding of both the practitioner
and the patient regarding the patient-provider
agreement of the patien t,
c. establish the rights of the pa tient in association
with treatment and the obligations of the patient in
relation to the responsible use, disc ontinuation of
use, and storage of opioid drugs, includin g any
restrictions on the refill of prescriptions or the
acceptance of opioid prescripti ons from practitioners ,
d. identify the specific medications and other mode s of
treatment, including physical therapy or exercise,
relaxation or psychological counselin g, that are
included as a part of the patient-provider agreement,
e. specify the measures the practitioner may employ to
monitor the compliance of the patient incl uding, but
not limited to, random specimen screens and pill
counts, and
f. delineate the process for terminating the agreement,
including the consequences if the practitioner has
ENGR. H. B. NO. 3073 Page 23 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
reason to believe that t he patient is not complying
with the terms of the agr eement. Compliance with the
"consent items" shall constitute a valid, informed
consent for opioid therapy. The practitioner shall be
held harmless from civil litigation for failur e to
treat pain if the event occurs because of nonadherence
by the patient with any of the provisions of the
patient-provider agreement;
46. 47. "Serious illness" means a medical illness o r physical
injury or condition that substantially affects quality o f life for
more than a short period of time . "Serious illness" includes, but
is not limited to, Alzheimer 's disease or related dementias, lung
disease, cancer, heart f ailure, renal failure , liver failure or
chronic, unremitting or intractable pain such as neuropathic pain;
and
47. 48. "Surgical procedure" means a procedure that is
performed for the purpose of struct urally altering the human body by
incision or destruct ion of tissues as part of the practice of
medicine. This term includes the diagnostic o r therapeutic
treatment of conditions or disease processes by use of instru ments
such as lasers, ultrasound, ioniz ing, radiation, scalpels, probes or
needles that cause localized alteration or transportation of live
human tissue by cutting, burning, vapori zing, freezing, suturi ng,
probing or manipulating by closed reduction for m ajor dislocations
ENGR. H. B. NO. 3073 Page 24 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
or fractures, or othe rwise altering by any mechanical, thermal,
light-based, electromagnetic or chem ical means.
SECTION 2. AMENDATORY 63 O. S. 2021, Section 2-309I, is
amended to read as follows:
Section 2-309I. A. A practitioner shall not issue an initi al
prescription for an opioid drug in a quantit y exceeding a seven-day
supply for treatment of acute pain . Any opioid prescription for
acute pain shall be for th e lowest effective dose of an immediate -
release drug.
B. Prior to issuing an initial prescrip tion for an opioid drug
in a course of treatmen t for acute or chronic pain, a practitioner
shall:
1. Take and document the resul ts of a thorough medical history,
including the experience of the patient with nonopio id medication
and nonpharmacological pain -management approaches and substance
abuse history;
2. Conduct, as appropriate, and document the results of a
physical examination;
3. Develop a treatment plan with particular attention focused
on determining the cause of pain of the patient;
4. Access relevant prescription monitoring information fr om the
central repository pursuant to Section 2-309D of this title;
5. Limit the supply of any opioid drug prescri bed for acute
pain to a duration of no more than seve n (7) days as determined by
ENGR. H. B. NO. 3073 Page 25 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the directed dosage and frequency of dosage; provided, howev er, upon
issuing an initial prescription for acute pain pu rsuant to this
section, the practitioner may issue one (1 ) subsequent prescription
for an opioid drug in a qua ntity not to exceed seven (7) days if:
a. the subsequent prescription is due to a major surgical
procedure or "confined to h ome" status as defined in
42 U.S.C., Section 1395n(a),
b. the practitioner prov ides the subsequent prescription
on the same day as t he initial prescription,
c. the practitioner provides written instructions on the
subsequent prescription indicating the ear liest date
on which the prescription may be filled, otherwise
known as a "do not fill until" date, and
d. the subsequent prescriptio n is dispensed no more than
five (5) days after the "do not fill until" date
indicated on the prescription;
6. In the case of a patient under the age of eighteen (18)
years, enter into a patient-provider agreement with a parent or
guardian of the patient ; and
7. In the case of a patient who is a pregnant woman, enter into
a patient-provider agreement with the patient.
C. No less than seven (7) d ays after issuing the initial
prescription pursuant to sub section A of this section, the
practitioner, after c onsultation with the patient, may issue a
ENGR. H. B. NO. 3073 Page 26 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
subsequent prescription for the drug to the patient in a quantity
not to exceed seven (7) days, provided that:
1. The subsequent prescripti on would not be deemed an initial
prescription under this section;
2. The practitioner determines the prescription is necessary
and appropriate to the treatm ent needs of the patient and documents
the rationale for the i ssuance of the subsequent prescripti on; and
3. The practitioner determines that issuance of the subsequent
prescription does not present an undue risk of abuse, addiction or
diversion and documents that determination.
D. Prior to issuing the initial pres cription of an opioid drug
in a course of treatment for ac ute or chronic pain and again prior
to issuing the third prescription of the course of treatme nt, a
practitioner shall discuss with th e patient or the parent or
guardian of the patient if the patien t is under eighteen (18) years
of age and is not an emanci pated minor, the risks associated with
the drugs being prescribed, including but not limited t o:
1. The risks of addiction and overd ose associated with opioid
drugs and the dangers of taking opioid drugs with alcohol,
benzodiazepines and other central ner vous system depressants;
2. The reasons why the pre scription is necessary;
3. Alternative treatments that may be available; and
4. Risks associated with the use of the drugs being prescribed,
specifically that opioids are highly ad dictive, even when tak en as
ENGR. H. B. NO. 3073 Page 27 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
prescribed, that there is a risk of developing a physical or
psychological dependence on the controlled dangerous substance, and
that the risks of taking more opioids tha n prescribed or mixing
sedatives, benzodiazepines or alcoh ol with opioids can re sult in
fatal respiratory depression.
The practitioner shall include a note in the medical rec ord of
the patient that the patient or the parent or guardian of the
patient, as applicable, has discuss ed with the practitioner the
risks of developing a physica l or psychological dependence on the
controlled dangerous substance and alternative treatments that may
be available. The applic able state licensing board of the
practitioner shall develop and make available to practitioners
guidelines for the discussion required pursuant to this subsection.
E. At the time of the issuance of the third prescriptio n for an
opioid drug, the practiti oner shall enter into a patient-provider
agreement with the patient.
F. When an opioid drug is continuous ly prescribed for thre e (3)
months or more for chronic pain, the practitio ner shall:
1. Review, at a minimum of eve ry three (3) months, the course
of treatment, any new information about the etiolo gy of the pain,
and the progress of the patient toward tre atment objectives and
document the results of that review;
2. In the first year of the patient-provider agreement, assess
the patient prior to eve ry renewal to determine whether the patient
ENGR. H. B. NO. 3073 Page 28 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
is experiencing problems asso ciated with an opioid use disorder as
defined by the Ameri can Psychiatric Association and document the
results of that assessment. Following one (1) ye ar of compliance
with the patient-provider agreement, the practitioner shall asses s
the patient at a min imum of every six (6) months;
3. Periodically make reason able efforts, unless clinically
contraindicated, to either stop the use of the controlled subs tance,
decrease the dosage, tr y other drugs or treatment modalities in an
effort to reduce the potentia l for abuse or the development of an
opioid use disorder as defined by the American Psychiatric
Association and document with specificity the efforts und ertaken;
4. Review the centr al repository information in accordance with
Section 2-309D of this title; and
5. Monitor compliance with the patient-provider agreement and
any recommendations that the patient seek a referral.
G. 1. Any prescription for ac ute pain pursuant to this s ection
shall have the words "acute pain" notated on the face of the
prescription by the practitioner.
2. Any prescription for chronic pain pursuant to this section
shall have the words " chronic pain" notated on the face of the
prescription by the practit ioner.
H. This section shall not apply to a prescriptio n for a patient
who:
1. Who has sickle cell disease;
ENGR. H. B. NO. 3073 Page 29 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. Who is in treatment for cancer or receiving aftercare cancer
treatment, receiving;
3. Who is receiving hospice care from a licensed hospice , or;
4. Who is receiving palliative care, as such term is de fined in
Section 2-101 of this title, in conjunction with a serious illness,
or;
5. Who is a resident of a long -term care facility, or to; or
6. For any medications that are being prescribed for use in the
treatment of substance abuse or opioid dependence.
I. Every policy, contract or plan delive red, issued, executed
or renewed in this state, or approved for issuance or renew al in
this state by the Insurance Commissioner, and every contract
purchased by the Employees Gr oup Insurance Division of the Office of
Management and Enterprise Services, on or after November 1, 2018,
that provides coverage for prescription drugs subject to a
copayment, coinsurance or deductible shall charge a copayment,
coinsurance or deductible fo r an initial prescription of an opioid
drug prescribed pursuant to this section that is either:
1. Proportional between the cost sharing for a thirty-day
supply and the amount of drugs the patient was prescribed; or
2. Equivalent to the cost sharing for a full thirty-day supply
of the drug, provided that no additional cost sharing may be charged
for any additional prescriptions for the remainder of the thirty-day
supply.
ENGR. H. B. NO. 3073 Page 30 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
J. Any practitioner authorized to prescribe an opioid drug
shall adopt and maintain a written policy or policies that include
execution of a written agreement to e ngage in an informed consent
process between the prescribing practitioner and qua lifying opioid
therapy patient. For the purposes of this section, "qualifying
opioid therapy patient" means:
1. A patient requiring opioid treatment for more than three (3)
months;
2. A patient who is pr escribed benzodiazepines and opioids
together for more than one twenty-four-hour period; or
3. A patient who is prescribed a dose of opioids that exceeds
one hundred (100) morphine equivalent doses.
K. Nothing in the Anti -Drug Diversion Act shall be cons trued to
require a practitioner to limit or forcib ly taper a patient on
opioid therapy. The standard of care requires effective and
individualized treatment for each patient as deemed appropriate by
the prescribing practitio ner without an administrative o r codified
limit on dose or quantity that is more restrictive than approved by
the Food and Drug Administration (FDA).
SECTION 3. It being immediately necessary for the preservation
of the public peace, health or safety, an emergency is he reby
declared to exist, by reason whereof this act shall take effect and
be in full force from and after its passage an d approval.
ENGR. H. B. NO. 3073 Page 31 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Passed the House of Representatives the 10th day of March, 2022.
Presiding Officer of the House
of Representatives
Passed the Senate the ___ day of __________, 2022.
Presiding Officer of the Senate